Key changes to the New Drugs and Clinical Trials (NDCT) Rules, 2019 have been announced by the Union Health Ministry with the goal of streamlining pharmaceutical research and development regulations and expediting drug development in India.
Pharmaceutical businesses will no longer need to apply for a test license from the Central pharmaceuticals Standard Control Organization (CDSCO) in order to create tiny amounts of pharmaceuticals for analysis, research, or evaluation in a non-commercial setting. Alternatively, businesses can move forward with development by sending the CDSCO a prior online notification. However, some high-risk categories, including cytotoxic medications, narcotic pharmaceuticals, and psychiatric compounds, are not covered by the exception.
According to the ministry, the modifications are compliant with Prime Minister Narendra Modi’s order to lessen the burden of regulations and facilitate commercial dealings. Pharmaceutical innovation and research will be greatly aided by the reform, which is anticipated to save at least 90 days in the drug development lifecycle.
The statutory processing period has been reduced from 90 days to 45 days for categories where test licenses are still required. The measure is anticipated to significantly reduce administrative workload because the CDSCO processes between 30,000 and 35,000 test license applications each year.
Another significant development is the elimination of the need for previous approval for some low-risk bioavailability and bioequivalency (BA/BE) studies. The generic medication business in particular will benefit from the fact that these studies can now start based on internet notification.
To guarantee a seamless implementation, specialized online modules will be introduced on the SUGAM site and the National Single Window System. According to the government, the changes will boost R&D-driven growth, improve regulatory effectiveness, and solidify India’s standing as a major international center for pharmaceutical research.
